Skip to content
Open access

ION775, a long-acting siRNA targeting APOC3: single-dose, 12-month results in participants with moderate hypertriglyceridemia

Oct 2026 · European Heart Journal · Vol 47 · 0 citations

TL;DR

Single subcutaneous doses of ION775 produced rapid, significant, dose-dependent, and durable reductions in apoC-III and TGs, with favorable effects on atherogenic lipoprotein measures and an acceptable safety profile through up to 12 months of follow-up.

Abstract

Reduction in apolipoprotein C-III (apoC-III) is an established strategy to lower plasma triglycerides (TGs) and TG-rich lipoproteins. To evaluate the safety, tolerability, and pharmacodynamics of ION775, an investigational GalNAc-conjugated small interfering RNA targeting APOC3 messenger RNA, in otherwise healthy adults with elevated TGs, and to characterize its effects on plasma apoC-III, fasting TGs, and atherogenic lipoproteins. This was a Phase 1, randomized, double-blind, placebo-controlled, single-ascending-dose study in adults with fasting TGs 150–500 mg/dL. Forty participants (30 ION775, 10 placebo) received a single subcutaneous dose of ION775 (10, 30, 100, 300, or 600 mg) or placebo and were followed for up to 12 months; 12-month follow-up is ongoing for the 600-mg cohort. The primary endpoint was safety. Prespecified pharmacodynamic endpoints included percent change from baseline in apoC-III, TGs, and other lipid parameters at 6 months versus placebo (Wilcoxon rank-sum test). This analysis reports safety and efficacy at 6 months, including mean percent change from baseline versus pooled placebo in apoC-III, TGs, non–HDL cholesterol (non–HDL-C), remnant cholesterol, and apolipoprotein B (apoB). Baseline mean (SD) apoC-III and TGs were 13.0 (3.4) mg/dL and 224.0 (69.2) mg/dL, respectively. ION775 was well tolerated, with no serious or severe adverse events and no injection-site reactions. ION775 produced rapid, sustained, dose-dependent reductions in apoC-III and TGs. At 6 months, mean percent changes in apoC-III from baseline were −54%, −74%, and −82% for the 30-, 100-, and 300-mg dose groups (p=0.0007 for all) versus +10% with placebo. Corresponding mean changes in TGs were −52% (p=0.005), −68% (p=0.0007), and −68% (p=0.0007) for 30, 100, and 300 mg, respectively, versus +0.2% with pooled placebo. At 6 months, ION775 100 and 300 mg reduced apoB by −20% (p=0.0013) and −29% (p=0.0007), non–HDL-C by −22% (p=0.0007) and −31% (p=0.0007), and remnant cholesterol by −69% (p=0.003) and −73% (p=0.003), respectively. At 6 months, 100% of ION775-treated participants across all dose groups achieved TG levels <150 mg/dL. At 12 months, mean reductions from baseline in apoC-III were −46% and −62%, and in TGs were −46% and −65%, in the 100- and 300-mg groups, respectively. Single subcutaneous doses of ION775 produced rapid, significant, dose-dependent, and durable reductions in apoC-III and TGs, with favorable effects on atherogenic lipoprotein measures and an acceptable safety profile through up to 12 months of follow-up. Phase 2 studies will evaluate ION775 in patients with more severe forms of hypertriglyceridemia.figure

Read PDF

Similar papers

Open access Oct 2026

HRS-7249, a small interfering RNA targeting apolipoprotein C3, in healthy subjects

Apolipoprotein C3 (APOC3) is involved in the metabolism of triglyceride (TG) and is a novel target for the treatment of hypertriglyceridemia. HRS-7249 is a small interfering RNA designed to disrupt and inhibit the expression of APOC3 and consequently lower TG level. This phase 1 study aimed to assess the s...

L. Zhu, T. Luo, X. Ren et al. · 0 citations
Open access Oct 2026

Apolipoprotein and inflammatory biomarker changes following marked triglyceride reduction with the GalNAc-conjugated APOC3 siRNA RBD5044

Profound TG reduction achieved by APOC3 siRNA therapy is associated with an apolipoprotein pattern resembling APOC3 heterozygous deficiency, as well as a coordinated anti-inflammatory response, suggesting that deep APOC3 silencing remodels lipoprotein composition and may contribute to inflammation resolution by modulat...

S. Nilsson, S. Ueckert, A. Gabrielsen et al. · 0 citations
Open access Oct 2026

EDP167, an ANGPTL3-target siRNA, showed favorable safety and lipid-lowering potential in Chinese healthy adult volunteers and subjects with mild dyslipidemia

In healthy volunteers and subjects with mild dyslipidemia, single subcutaneous doses of EDP167 demonstrated a favorable safety and tolerability profile and a dose-dependent reduction in ANGPTL3 and substantial reductions in TG, LDL-C, non-HDL-C, ApoB and remnant-C were observed.

J. Wang, B. Jiang, Shi-Long Zhong et al. · 0 citations
Open access Oct 2026

Safety, tolerability, pharmacokinetics and pharmacodynamics of HRS-1301, an oral PCSK9 inhibitor, in healthy participants: a first-in-human, randomized, double-blind, placebo-controlled phase I trial

Inhibition of proprotein convertase subtilisin/kexin type 9 (PCSK9) is a proven therapeutic strategy for reducing plasma low density lipoprotein-cholesterol (LDL-C). HRS-1301 is an oral small molecule PCSK9 inhibitor designed to prevent LDL receptor degradation, representing a novel therapeutic approach for dysli...

Shi-Long Zhong, X. Wang, P. Wang et al. · 0 citations
Open access Oct 2026

Efficacy and safety of SYH2053 in patients with primary hypercholesterolemia or mixed dyslipidemia: a phase II, multicenter, randomized, double-blind, placebo- and active-controlled trial

SYH2053 is a novel small interfering RNA (siRNA) drug targeting proprotein convertase subtilisin/kexin type 9 (PCSK9), with optimized full-sequence chemical modification and N-acetylgalactosamine conjugation, which demonstrated a stable and sustained lipid-lowering efficacy in the phase I study in heathy particip...

F. Wang, Shu-Yi Zeng, S. Zhang et al. · 0 citations
Open access Oct 2026

Long-term efficacy and safety of olezarsen in patients with severe hypertriglyceridemia

Olezarsen, an antisense oligonucleotide that targets the mRNA for apolipoprotein C-III, reduced triglycerides (TGs) in patients with severe hypertriglyceridemia (sHTG, TG >500 mg/dL) by 50-72% at 6 months in two double-blinded placebo-controlled randomized clinical trials (RCTs, CORE-TIMI 72a, CORE2-TIMI 72b)....

R. Giugliano, N. Marston, B. Bergmark et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.